Arizona Health Sciences

Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

TitleTargeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.
Publication TypeJournal Article
Year of Publication2017
AuthorsGrenald SA, Doyle TM, Zhang H, Slosky LM, Chen Z, Largent-Milnes TM, Spiegel S, Vanderah TW, Salvemini D
JournalPain
Volume158
Issue9
Pagination1733-1742
Date Published2017 Sep
ISSN1872-6623
Abstract

Metastatic bone pain is the single most common form of cancer pain and persists as a result of peripheral and central inflammatory, as well as neuropathic mechanisms. Here, we provide the first characterization of sphingolipid metabolism alterations in the spinal cord occurring during cancer-induced bone pain (CIBP). Following femoral arthrotomy and syngenic tumor implantation in mice, ceramides decreased with corresponding increases in sphingosine and the bioactive sphingolipid metabolite, sphingosine 1-phosphate (S1P). Intriguingly, de novo sphingolipid biosynthesis was increased as shown by the elevations of dihydro-ceramides and dihydro-S1P. We next identified the S1P receptor subtype 1 (S1PR1) as a novel target for therapeutic intervention. Intrathecal or systemic administration of the competitive and functional S1PR1 antagonists, TASP0277308 and FTY720/Fingolimod, respectively, attenuated cancer-induced spontaneous flinching and guarding. Inhibiting CIBP by systemic delivery of FTY720 did not result in antinociceptive tolerance over 7 days. FTY720 administration enhanced IL-10 in the lumbar ipsilateral spinal cord of CIBP animals and intrathecal injection of an IL-10 neutralizing antibody mitigated the ability of systemic FTY720 to reverse CIBP. FTY720 treatment was not associated with alterations in bone metabolism in vivo. Studies here identify a novel mechanism to inhibit bone cancer pain by blocking the actions of the bioactive metabolites S1P and dihydro-S1P in lumbar spinal cord induced by bone cancer and support potential fast-track clinical application of the FDA-approved drug, FTY720, as a therapeutic avenue for CIBP.

DOI10.1097/j.pain.0000000000000965
Alternate JournalPain
PubMed ID28570482
PubMed Central IDPMC5580091
Grant ListP30 CA016059 / CA / NCI NIH HHS / United States
R01 CA142115 / CA / NCI NIH HHS / United States
R01 GM043880 / GM / NIGMS NIH HHS / United States
Faculty Member Reference: 
Tally Largent-Milnes, Ph.D.
Todd Vanderah, Ph.D.